| Agents and crystals for improving excretory potency of urinary bladder -> Monitor Keywords |
|
|
 
Agents and crystals for improving excretory potency of urinary bladderRelated Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Designated Organic Active Ingredient Containing (doai), Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms DoaiAgents and crystals for improving excretory potency of urinary bladder description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20060281725, Agents and crystals for improving excretory potency of urinary bladder. Brief Patent Description - Full Patent Description - Patent Application Claims
[0001] This is a continuation-in-part of U.S. Serial No. 09/787,288, filed March 15, 2001. BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] The present invention relates to drugs, particularly agents for further improving excretory potency of the urinary bladder. The present invention further relates to crystals and pharmaceutical compositions comprising the crystals of a tricyclic, condensed, heterocyclic compound which inhibit acetylcholinesterase and improve excretory potency of the urinary bladder. [0004] 2. Description of Related Art [0005] Inferior uropathy is a general term for subjective or objective disorders in a process through accumulation of urine (urinary storage) till excretion (urination), which may be classified into urinary cumulative disorders (incontinence of urine, pollakiuria, etc.), dysuria (difficulty of urination, scalding, obstruction of urinary tract, etc.), and the like. Inferior uropathy in the aged, particularly dysuria, especially dysuria caused by prostatomegaly, becomes a great problem of public concern with the advance of a recent aging society, though inferior uropathy may also be found in the youth. [0006] Urination is, under the control of the urination center, controlled by the peripheral nervous system involving a parasympathetic nerve such as the pelvic nerve, the sympathetic nerve such as the hypogastric nerve, and the somatic nerve such as the pudendal nerve, and it is suggested that a variety of neurotransmitters (e.g., acetylcholine, adrenaline, ATP, Substance P, neuropeptide Y, etc.) are involved in urination. [0007] As agents for treatment of dysuria, particularly difficulty of urination, those for increasing contraction of the muscles of the urinary bladder (detrusor) or relaxing sphincter muscle of the urethra to reduce urethral resistance have been used. As the agents acting on the muscle of the urinary bladder to increase the contraction, for example, cholinergic agents such as bethanechol, acetylcholinesterase inhibitors such as distigmine, and the like have been used. Bethanechol however is incompatible with pregnant women, peptic ulcers, organic ileus, asthma, hyperthyroidism, etc., because it has adverse effects such as epiphora, sweating, gastro-intestinal disorders, stomachache, etc. No entirely satisfactory drugs have yet been found. [0008] As the acetylcholinesterase inhibitors increasing contraction of the muscle of the urinary bladder, carbamate-type acetylcholinesterase inhibitors having a carbamate structure (--OCON--) in its molecule (e.g., distigmine, neostigmine, etc.) are known. These carbamate-type acetylcholinesterase inhibitors are known to express their inhibitory effect based on the carbamate structure which is characteristic of the molecule (Goodman & Gilman's The PHARMACOLOGICAL BASIS OF THERAPEUTICS, Ninth ed., McGraw-Hill, New York, p. 161-176). However, it is known that, for example, distiginine is insufficient in its clinical efficacy since it contracts the muscle of the urinary bladder with constriction of the muscle of the urethra to increase urethral resistance and consequently make the voiding flow rate worse. In addition, neostigmine has not been used in therapy because of the short duration of its action (Takamichi Hattori and Kosaku Yasuda, "Sinkeiinseiboukou-No-Sindan-To-Chiryou (Diagnosis and Therapy of Neurogenic Bladder)", 2nd Ed., p. 105-106, p. 139, Igaku-Shoin Ltd. Tokyo). [0009] On the other hand, a variety of amine compounds which have an acetylcholinesterase inhibiting effect and are different from carbamate-type inhibitors in their structure have been reported as follows. [0010] (1) Compounds of the following formula: wherein B represents an optionally substituted saturated or unsaturated 5- to 7-membered aza-heterocyclic group; A is a bond or alkylene or alkenylene optionally substituted with hydrocarbon residue, oxo or hydroxy; indicates a single bond or double bond (where when A is a bond, indicates a single bond); R.sub.2 and R.sub.3 each represent independently hydrogen or optionally substituted hydrocarbon residue (but they are not hydrogen concurrently) or they may be taken with the adjacent nitrogen atom to form a cyclic amino group; n is 0, 1 or 2; and p is 1 or 2; or salts thereof as described in EP-A-0 378 207. [0011] Such compounds as described are exemplified by 3-[1-(phenylmethyl)piperidin-4-yl]-1-[4-(pyrrolidin-1-yl)phenyl]-1-propan- one, 1-[4-(N,N-dimethylamino)phenyl]-3-[1-(phenylmethyl)piperidin-4-yl]-1-- propanone, and the like. [0012] (2) Compounds of the following formula. wherein X represents R.sup.1--N<(R.sup.1 is hydrogen, optionally substituted hydrocarbon group or optionally substituted acyl), oxygen or sulfur; R.sup.2 represents hydrogen or optionally substituted hydrocarbon group; the ring A represents an optionally substituted benzene ring; k is an integer of 0-3; m indicates an is of 1-8; and n is an integer of 1-6; or salts thereof as described in Japanese Patent Unexamined Publication No. (hereinafter referred to as JP-A) 5-140149/1993. [0013] Such compounds as described above are exemplified by 3-[1-(phenylmethyl)piperidin-4-yl]-1-(2,3-dihydro-1H-indol-5-yl)-1-propan- one, 3-[1-(phenylmethyl)piperidin-4-yl]-1-(2,3,4,5-tetrahydro-1H-1-benzaze- pin-8-yl)-1-propanone, and the like. [0014] (3) Compounds of the following formula: wherein R.sup.1 represents hydrogen, optionally substituted hydrocarbon group or optionally substituted acyl; the ring A represents an optionally further substituted benzene ring; n is an integer of 1 to 10; R.sup.2, R.sup.3 and R.sup.4 are the same or different representing hydrogen or optionally substituted hydrocarbon group, or R.sup.3 and R.sup.4 may be taken with the adjacent nitrogen atom to form an optionally substituted heterocyclic group, and R.sup.2 may be different respectively according to repetition of n; k is an integer of 0 to 3; m is an integer of 1 to 8; provided that when k=0 and m=2, then n>1; or salts thereof as described in JP-A 6-166676/1994. [0015] Such compounds as described above are exemplified by 3-[1-(phenylmethyl)-2,3,4,5 -tetrahydro-1H-3-benzazepin-7-yl]-3 -[4-(phenylmethyl)piperazin-1-yl]-1-propanone, 1-[2-(phenylmethyl)-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[4-(phenyl- methyl)piperazin-1-yl]-1-propanone, and the like. [0016] (4) Compounds of the following formula: wherein the ring A represents an optionally further substituted benzene ring; the ring B represents an optionally substituted non-aromatic heterocyclic ring containing the same or different, two or more hetero atoms; R.sup.1 represents hydrogen or optionally substituted hydrocarbon group, which may be different according to a repetition of n; Y represents an optionally substituted amino or an optionally substituted nitrogen-containing saturated heterocycle; and n is an integer of 1 to 10; or salts thereof as described in JP-A 6-206875/1994. [0017] Such compounds as described above are exemplified by 3-[1-(phenylmethyl)piperidin-4-yl]-1-(2,3,4,5-tetrahydro-1,4-benzoxazepin- -7-yl]-1-propanone and the like. [0018] (5) JP-A 7-206854/1995 discloses the formula: wherein Ar represents an optionally substituted tricyclic condensed benzene ring group condensed with at least one heterocycle; n is an integer of 2 to 10; R.sup.1 represents hydrogen or optionally substituted hydrocarbon group, which may be different according to a repetition of n; Y represents 4-piperidinyl, 1-piperadinyl or 4-benzyl-1-piperidinyl, each of which may have a substituent or substituents. [0019] Such compounds as described above are exemplified by 8-[3-[1-(phenylmethyl)-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-- pyrrolo[3,2,1-ij]quinolin-4-one, 1-(1,2,2a,3,4,5-hexahydrobenz[cd] indol-6-yl)-3-[-(phenylmethyl)-4-piperidinyl]-1-propanone, and the like. [0020] Also described in the Japanese Patent Kokai Publication is an amorphous substance of 8-[3-[1-[(3-fluorophenyl)methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetr- ahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one or a salt thereof, which possesses an action to inhibit acetylcholine esterase. [0021] (6) Compounds of the following formula: wherein Ar represents an optionally substituted tetracyclic condensed heterocyclic group; n is an integer of 1 to 10; R.sup.1 represents hydrogen or optionally substituted hydrocarbon group, which may be different according to a repetition of n; Y represents an amino or nitrogen-containing saturated heterocyclic group, each of which may have a substituent or substituents; or salts thereof as described in JP-A 7-309835/1995. [0022] Such compounds as described above are exemplified by 3-[3-[1-(phenylmethyl)-4-piperidinyl]-1-oxopropyl)-7,11 b, 12,13-tetrahydro-5H-isoindolo[2,1-b][2]benzazepin-7-one, 2-[1-oxo-3-[1-(phenylmethyl)-4-piperidinyl]-4,5,7a,8,9,10,11,11a-octahydr- o-6H-pyrido[3,2,1-jk]carbazol-6-one, and the like. [0023] (7) Amine compounds described in WO 93/07140, PCT Japanese Patent Unexamined Publication No. (hereinafter referred to as PCT JP-A) 6-500794/1994, JP-A 4-234845/1992, JP-A 6-116237/1994, JP-A 7-109275/1995, WO 97/37992, JP-A 5-148228/1993, JP-A 5-194359/1993, JP-A 6-507387/1994, PCT JP-A 7-502272/1995, PCT JP-A 8-511515/1996, JP-A 6-41070/1994, JP-A 5-9188/1993, JP-A 5-279355/1993, JP-A 5-320160/1993, JP-A 6-41125/1994, JP-A 5-345772/1993, JP-A 7-502529/1995, JP-A 64-79151/1989, JP-A 62-234065/1987, JP-A 4-235161/1992, JP-A 4-21670/1992, JP-A 9-268176/1997; and so on. Continue reading about Agents and crystals for improving excretory potency of urinary bladder... Full patent description for Agents and crystals for improving excretory potency of urinary bladder Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Agents and crystals for improving excretory potency of urinary bladder patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Agents and crystals for improving excretory potency of urinary bladder or other areas of interest. ### Previous Patent Application: Methods for treating shock Next Patent Application: 3-substituted beta-lactamyl vasopressin v1a antagonists Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Agents and crystals for improving excretory potency of urinary bladder patent info. IP-related news and info Results in 0.1783 seconds Other interesting Feshpatents.com categories: Canon USA , Celera Genomics , Cephalon, Inc. , Cingular Wireless , Clorox , Colgate-Palmolive , Corning , Cymer , 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
